Publications by authors named "Janusz Tomaszewski"

Article Synopsis
  • Pregnancy causes changes in sexual functioning for women due to physiological, anatomical, and hormonal shifts in their bodies.
  • A study surveyed 148 pregnant women, revealing that over half reported a moderate desire for sexual intercourse during pregnancy, with many experiencing a decreased need compared to before pregnancy.
  • Statistical analysis indicated significant relationships between women's education levels and their sexual needs prior to pregnancy, while a majority reported reduced sexual satisfaction and fewer sexual encounters during pregnancy.
View Article and Find Full Text PDF

Objective: To assess long term safety of extended repeated 3-month courses of ulipristal acetate (UPA) 10 mg/day, for up to 8 courses, with focus on endometrial and laboratory safety parameters.

Methods: This long-term, multi-center, open-label cohort, follow up study consisted of up to 8 consecutive 3-month courses of daily UPA 10 mg, each separated by a drug free period of 2 spontaneous menstrual bleeds. Sixty-four pre-menopausal women, with moderate to severe symptomatic uterine myoma(s) and heavy bleeding were enrolled and were studied for approximately 4 years.

View Article and Find Full Text PDF

Objective: To investigate the efficacy and safety of ulipristal acetate (UPA) for long-term treatment of symptomatic uterine fibroids.

Design: Repeated intermittent open-label UPA courses, each followed by randomized double-blind norethisterone acetate (NETA) or placebo.

Setting: European clinical gynecology centers.

View Article and Find Full Text PDF

Background: The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear.

Methods: In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg).

View Article and Find Full Text PDF